Korea Investment CORP Reduces Stake in Johnson & Johnson

The institutional investor cut its position in the healthcare giant by 13.5% in the third quarter.

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Korea Investment CORP, a major institutional investor, reduced its stake in Johnson & Johnson (NYSE:JNJ) by 13.5% in the third quarter, according to a recent SEC filing. The firm now owns approximately 1.59 million shares of the healthcare company, valued at $294 million, making it one of Johnson & Johnson's top 25 shareholders.

Why it matters

This move by a major institutional investor provides insight into the market's sentiment towards Johnson & Johnson. As a leading global healthcare company, changes in ownership of JNJ stock can signal broader trends in the industry and investor confidence in the company's performance and outlook.

The details

According to the filing, Korea Investment CORP sold 247,334 shares of Johnson & Johnson stock during the third quarter. The firm now holds a $294 million position in JNJ, representing approximately 0.6% of its total portfolio. Johnson & Johnson is the 25th largest holding for the institutional investor.

  • Korea Investment CORP filed the SEC disclosure on March 8, 2026, detailing its reduced stake in Johnson & Johnson as of the third quarter of 2025.

The players

Korea Investment CORP

A major institutional investor that manages a diversified portfolio of global assets.

Johnson & Johnson

A multinational healthcare company that develops, manufactures, and markets pharmaceutical, medical device, and consumer health products.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Korea Investment CORP's stake in Johnson & Johnson, a bellwether healthcare company, could signal broader market concerns or a shift in investment strategy by the institutional investor. However, Johnson & Johnson remains a top holding, indicating the firm's continued confidence in the company's long-term prospects.